Oregon will receive $10.1 million for drug prevention and treatment services as part of a nationwide settlement with eight opioid manufacturers. <\/p>\n
Opioid manufacturing companies including Mylan, Hikma, Amneal, Apotex, Indivior, Sun, Alvogen and Zydus agreed to pay a total of $720 million to Oregon and eight other states. <\/p>\n
The settlement adds to the $700 million Oregon secured since July 2021, including a $66 million settlement<\/a> from the Sackler family and Purdue Pharma in June. <\/p>\n Of the funds, 45% will go toward the state\u2019s opioid settlement fund<\/a> and 55% will go toward prevention and recovery programs in counties and cities. Oregon\u2019s Settlement Prevention, Treatment and Recovery Board<\/a> has plans to distribute the funds through 2038. <\/p>\n Attorney General Dan Rayfield said in a news release that opioid makers must be accountable for the harm they\u2019ve caused to families. <\/p>\n \u201cNo amount of money can rewind the clock, but this money will allow us to continue building a future free from this crisis by investing in drug treatment, prevention and recovery support across our state,\u201d he said in the release. <\/p>\n The other states involved in the settlement are California, Colorado, Illinois, New York, North Carolina, Tennessee, Utah and Virginia.<\/p>\n — Mia Maldonado, Oregon Capital Chronicle<\/p>\n Oregon Capital Chronicle is part of States Newsroom<\/a>, the nation\u2019s largest state-focused nonprofit news organization.<\/p>\n If you purchase a product or register for an account through a link on our site, we may receive compensation. By using this site, you consent to our User Agreement<\/a> and agree that your clicks, interactions, and personal information may be collected, recorded, and\/or stored by us and social media and other third-party partners in accordance with our Privacy Policy.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Oregon will receive $10.1 million for drug prevention and treatment services as part of a nationwide settlement with…\n","protected":false},"author":3,"featured_media":67815,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[13890,1230,18742,210,1083,1060,13894,3535,24651,46953,67,132,68],"class_list":{"0":"post-67814","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-bottle","9":"tag-drugs","10":"tag-generic","11":"tag-health","12":"tag-medical","13":"tag-medication","14":"tag-percocet","15":"tag-prescription","16":"tag-studio","17":"tag-tablets","18":"tag-united-states","19":"tag-unitedstates","20":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114864292142714120","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/67814","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=67814"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/67814\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/67815"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=67814"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=67814"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=67814"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}